CN108349962A - 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 - Google Patents

取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 Download PDF

Info

Publication number
CN108349962A
CN108349962A CN201680045318.9A CN201680045318A CN108349962A CN 108349962 A CN108349962 A CN 108349962A CN 201680045318 A CN201680045318 A CN 201680045318A CN 108349962 A CN108349962 A CN 108349962A
Authority
CN
China
Prior art keywords
alkyl
optionally
fluoroalkyl
optionally replaced
key
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680045318.9A
Other languages
English (en)
Chinese (zh)
Inventor
M.A.西迪基
S.西布拉特
M.德里
L.康斯坦蒂诺-福盖特
C.格兰德-迈特雷
X.郭
S.斯里瓦斯塔瓦
G.W.希普斯
A.B.库珀
N.布鲁诺-拉图尔
V.L.李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ban Tower Pharmaceutical Co Ltd
Original Assignee
Ban Tower Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ban Tower Pharmaceutical Co Ltd filed Critical Ban Tower Pharmaceutical Co Ltd
Publication of CN108349962A publication Critical patent/CN108349962A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680045318.9A 2015-06-01 2016-06-01 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法 Pending CN108349962A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562169376P 2015-06-01 2015-06-01
US62/169,376 2015-06-01
PCT/US2016/035288 WO2016196644A1 (en) 2015-06-01 2016-06-01 Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Publications (1)

Publication Number Publication Date
CN108349962A true CN108349962A (zh) 2018-07-31

Family

ID=56118071

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680045318.9A Pending CN108349962A (zh) 2015-06-01 2016-06-01 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法

Country Status (9)

Country Link
US (2) US10537558B2 (de)
EP (1) EP3303332A1 (de)
JP (1) JP6707630B2 (de)
CN (1) CN108349962A (de)
BR (1) BR112017025851A2 (de)
CA (1) CA3025492A1 (de)
IL (1) IL255898A (de)
MX (1) MX2017015456A (de)
WO (1) WO2016196644A1 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603254A (zh) * 2016-11-30 2019-12-20 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110769823A (zh) * 2016-11-30 2020-02-07 班塔姆制药有限责任公司 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN110950848A (zh) * 2018-09-27 2020-04-03 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN114867724A (zh) * 2019-05-31 2022-08-05 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
CN115515685A (zh) * 2020-03-03 2022-12-23 皮克医疗公司 Eif4e抑制剂及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10537558B2 (en) 2015-06-01 2020-01-21 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2019236966A2 (en) 2018-06-07 2019-12-12 Bantam Pharmaceutical, Llc Methods of treatment of cancer with substituted pyrrole and pyrazole compounds and diagnosis of cancers susceptible to treatment with substituted pyrrole and pyrazole compounds
EP3846793B1 (de) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e-inhibitoren und verwendungen davon
EP4053123A4 (de) 2019-11-01 2023-10-11 Unimatec Co., Ltd. Fluorierte pyrimidinverbindung und verfahren zu ihrer herstellung

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468979B1 (en) * 1998-07-30 2002-10-22 Zambon Group S.P.A. Erythromycin derivatives with antibiotic activity
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2009027393A2 (en) * 2007-08-27 2009-03-05 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2264017A1 (de) * 2008-04-04 2010-12-22 Takeda Pharmaceutical Company Limited Heterocyclisches derivat und seine verwendung
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
TR200302047T4 (tr) * 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
WO2004089303A2 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
KR101608259B1 (ko) 2008-04-28 2016-04-01 교린 세이야꾸 가부시키 가이샤 시클로펜틸아크릴산아미드 유도체
ES2650744T3 (es) * 2010-12-14 2018-01-22 Electrophoretics Limited Inhibidores de la caseína quinasa 1 delta (CK1delta)
AU2015236855B2 (en) 2014-03-27 2018-11-01 Cancer Research Technology Limited Pyridyl piperidines
WO2016169886A1 (en) 2015-04-24 2016-10-27 Syngenta Crop Protection Ag Pesticidally active polycyclic derivatives with sulfur substituted five-membered ring heterocyles
US10537558B2 (en) 2015-06-01 2020-01-21 Bantam Pharmaceutical, Llc Substituted pyrazole and pyrrole compounds and methods for using them for inhibition of initiation of translation and treatment of diseases and disorders relating thereto

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468979B1 (en) * 1998-07-30 2002-10-22 Zambon Group S.P.A. Erythromycin derivatives with antibiotic activity
US20030220356A1 (en) * 2002-04-04 2003-11-27 Prabha Ibrahim ABCA-1 elevating compounds
WO2004094395A2 (en) * 2003-04-18 2004-11-04 Merck & Co., Inc. Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
WO2009027393A2 (en) * 2007-08-27 2009-03-05 Basf Se Pyrazole compounds for controlling invertebrate pests
EP2264017A1 (de) * 2008-04-04 2010-12-22 Takeda Pharmaceutical Company Limited Heterocyclisches derivat und seine verwendung
WO2014066304A1 (en) * 2012-10-22 2014-05-01 Egenix, Inc. Compositions and methods for treating or preventing diseases or disorders associated with misregulated eif4e

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SAMIA M. RIDA，等: "Synthesis of Novel Benzofuran and Related Benzimidazole Derivatives for Evaluation of In Vitro Anti-HIV-1, Anticancer and Antimicrobial Activities", 《ARCH PHARM RES》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110603254A (zh) * 2016-11-30 2019-12-20 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110769823A (zh) * 2016-11-30 2020-02-07 班塔姆制药有限责任公司 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN110603254B (zh) * 2016-11-30 2024-04-12 班塔姆制药有限责任公司 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
CN110950848A (zh) * 2018-09-27 2020-04-03 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN110950848B (zh) * 2018-09-27 2024-03-26 徐诺药业 新型氨基吡唑类衍生物的合成与应用
CN114867724A (zh) * 2019-05-31 2022-08-05 班塔姆制药有限责任公司 用于制备噻唑基吡唑甲酸及其中间体的方法
CN115515685A (zh) * 2020-03-03 2022-12-23 皮克医疗公司 Eif4e抑制剂及其用途

Also Published As

Publication number Publication date
CA3025492A1 (en) 2016-12-08
EP3303332A1 (de) 2018-04-11
US20200261424A1 (en) 2020-08-20
JP2018521119A (ja) 2018-08-02
MX2017015456A (es) 2018-11-29
BR112017025851A2 (pt) 2018-10-16
JP6707630B2 (ja) 2020-06-10
US10537558B2 (en) 2020-01-21
US20180311218A1 (en) 2018-11-01
IL255898A (en) 2018-01-31
WO2016196644A1 (en) 2016-12-08
US11602526B2 (en) 2023-03-14

Similar Documents

Publication Publication Date Title
CN108349962A (zh) 取代的吡唑和吡咯化合物以及使用其用于抑制翻译起始和治疗与其相关的疾病和病症的方法
CN111295382B (zh) 作为法尼酯x受体调节剂的桥联双环化合物
TWI527811B (zh) 作爲溴結構域抑制劑的苯並咪唑衍生物
CN101370796B (zh) 作为11β-HSD1抑制剂的噻唑类
CN104822687B (zh) 抗纤维化吡啶酮类
JP5557832B2 (ja) 置換４−ヒドロキシピリジン−５−カルボキサミド
CN114728912A (zh) Mta-协同prmt5抑制剂
CN110769823A (zh) 使用被取代的吡唑和吡咯化合物以及治疗过度增生性疾病的方法
CN108200760A (zh) 作为rsv抑制剂的苯并二氮杂*衍生物
CN110337294A (zh) 作为cftr增效剂的吡咯并嘧啶
CN107624112A (zh) 乳酸脱氢酶的小分子抑制剂及其使用方法
KR20160055199A (ko) 아릴 에테르 및 이의 용도
TW201536768A (zh) 作為鈉通道抑制劑的雙環磺醯胺化合物
TW201736362A (zh) 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
CN106456582A (zh) TrkA 激酶抑制剂、组合物及其方法
CN110603254A (zh) 被取代的吡唑化合物以及使用其治疗过度增生性疾病的方法
BR112014010617B1 (pt) Derivados de 2-(1,2,3-triazol-2-il)benzamida e 3-(1,2,3-triazol-2-il)picolinamida como antagonistas do receptor de orexina
TWI773718B (zh) 聚-adp核糖聚合酶（parp）抑制劑
CN111356695B (zh) 新的三环化合物
CN114450274A (zh) 作为lrrk2抑制剂的吲唑及氮杂吲唑
WO2023045960A1 (zh) 一种吡啶类衍生物及其用途
CN113727973A (zh) 可用作类法尼醇x受体调节剂的取代酰胺化合物
CN101679447A (zh) 嘧啶并二氮杂酮衍生物
CN101663276A (zh) 用作激酶抑制剂的2-氨基吡啶衍生物
CN110177784A (zh) 一种含芳环化合物、其制备方法、药物组合物及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

WD01 Invention patent application deemed withdrawn after publication